Join the Avastin group to help and get support from people like you.
Avastin News
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
MONDAY, May 12, 2025 – The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors, according...
FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin
BRIDGEWATER, New Jersey and BENGALURU, Karnataka, India, April 10, 2025 – Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food...
New Hope Against a Rare, Aggressive Form of Thyroid Cancer
MONDAY, Oct. 28, 2024 – Most thyroid cancers are slow-moving and, if caught early, curable. But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) – a rare and...
Combo Treatment Doubles Survival for Patients With Advanced Kidney Cancer
TUESDAY, Sept. 17, 2024 – A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer. Researchers at Roswell Park Comprehensive Cancer...
FDA Approves Avzivi (bevacizumab-tnjn), a Biosimilar to Avastin
GUANGZHOU, China, Dec. 7, 2023 /PRNewswire/ – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA – May 29, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Medwatch Alert: Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide Recall for all Lots of Bevacizumab
August 30, 2019 – AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are...
FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin
Friday, June 28, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to...
FDA Medwatch Alert: AmEx Pharmacy Issues Voluntary Nationwide Recall for one Lot of Bevacizumab 1.25mg/0.05mL 31 G Syringe Due to Reported Defective Delivery System
April 29, 2019 – AmEx Pharmacy is voluntarily recalling one Lot of Bevacizumab 1.25mg/0.05mL 31G Injectable to the consumer/user level. The Monoject Syringe of this product may become difficult to...
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
South San Francisco, CA – December 6, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved...
FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
South San Francisco, CA – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® ...
FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
South San Francisco, CA – December 5, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted full...
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...
Further information
Related condition support groups
Colorectal Cancer, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma